DERMAGNOSTIX Pioneering diagnostics in dermatology and cancer
- Coordinator
- Dermagnostix GmbH, Germany
- Runs
- 1 October 2022 to 30 September 2024
- Status
- Finished
- EU funding
- €2.5m
- Total cost
- €5.2m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190175375
What the project is doing
In the project's own words, from its summary on CORDIS.
At Dermagnostix, we envision the next level for molecular diagnostics in human skin to improve patients’ lives and clinical practice in dermatology. Skin diseases are the 4th most relevant human illnesses according to loss of quality of life. Conventional diagnostics in dermatology based on clinical view and histopathology are imprecise and subjective, resulting in up to 50% of misdiagnosed cases and insufficient or harmful therapies.
At Dermagnostix, we have developed a comprehensive technological platform for fast and objective molecular diagnostics in dermatology to reduce health care costs and improve patient treatment. Our fully automated platform delivers results within 90 min and testing can be run everywhere and at any time. Our easy-to-handle diagnostic device brings objective and precise skin diagnostics to reality allowing simultaneous detection of up to 40 different molecular targets within one single test.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Dermagnostix GmbH | Friedberg | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI